Novel compounds and their effects on feeding behaviour

An analogue of PYY comprising an amino acid sequence represented by formula (I)

• (SEQ ID NO:
• 1)
• Xaa2-Ile-Xaa4-Pro-Xaa6-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Xaa16-Xaa17-
• Xaa18-Xaa19-Tyr-Xaa21-Xaa22-Ala-Leu-Xaa25-His-Tyr-Leu-Asn-Xaa30-Val-Thr-
• Arg-Gln-Arg-Tyr-NH2
• (I)
• wherein
• Xaa2 is selected from the group consisting of Pro and Gly;
• Xaa4 is selected from the group consisting of Arg, His, Lys and Orn;
• Xaa6 is selected from the group consisting of Asp, Glu, His, Lys, Ser, Thr and Val;
• Xaa16 is selected from the group consisting of Asn, Asp, Gln and Glu;
• Xaa17 is selected from the group consisting of Ile, Leu and Val;
• Xaa18 is selected from the group consisting of Ala, Asn, Asp and Val;
• Xaa19 is selected from the group consisting of Arg and His;
• Xaa21 is selected from the group consisting of His, Phe, Trp and Tyr;
• Xaa22 is selected from the group consisting of Ala, Ile, Leu and Val;
• Xaa25 is selected from the group consisting of Arg, Gln and His;
• and
• Xaa30 is selected from the group consisting of Arg, His, Leu and Lys;
• or a compound that is a variant and/or derivative thereof;
• or a salt and/or solvate thereof, including a salt of such a variant and/or derivative, and a solvate of such a variant and/or derivative and/or salt,
• a variant being an amino acid sequence having up to two amino acids other than Xaa4, Xaa6, Xaa16, Xaa17, Xaa18, Xaa19, Xaa21, Xaa22, Xaa25 and Xaa3° replaced with a different amino acid.